Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE or thermal ablation plus targeted therapy, sintilimab, and chemotherapy for gastric cancer with liver metastases
ChiCTR2200057726Phase 2Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, trastuzumab, sintilimab, oxaliplatin and tegafur in gastric cancer (GC) and hepatic metastasis, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Progression-free survival and Objective response rate. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)hepatic metastasis
Beyond the preview
Go deeper on ChiCTR2200057726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057726.